NCT02198924View on ClinicalTrials.gov

Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

246

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions

PainInflammation

Interventions

DRUG

Parecoxib and Celecoxib

Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.

DRUG

placebo

control patients are supplied with the corresponding placebo with the same instructions.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT02198924 - Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients | Biotech Hunter | Biotech Hunter